Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangart has begun enrolling patients in two parallel European phase III trials of Hemospan, its blood substitute drug.
Subscribe to our email newsletter
Hemospan is the first oxygen therapeutic specifically engineered to target oxygen delivery to tissues. No similar therapeutic agents are currently on the market in Europe or the US.
More than 800 elective orthopedic surgery patients will be enrolled in the studies, which are designed to gauge the ability of Hemospan to prevent and treat hemodynamic instability, especially hypotension, or low blood pressure, during their operations.
The goal is to determine if Hemospan can help patients avoid hypotension during elective surgery. Hypotension is one of the key indicators for blood transfusion in such patients.
According to Sangart, research has shown that Hemospan’s oxygen delivery mechanism may provide a safe and effective alternative to blood transfusions. Blood transfusions are becoming more common worldwide despite the increased safety concerns in many developing countries.